Weekly Digest – June 2025 Weekly Digest – June 2025 17 June 2025: FDA grants orphan drug designation to Medicovestor’s first-in-class ADC for pancreatic cancer The FDA has granted Orphan Drug Designation to Medicovestor’s lead candidate, ADoBind MC001, for treating […]
Weekly Digest – June 2025 Weekly Digest – June 2025 17 June 2025: Boan receives FDA IND clearance for Its CD228-directed ADC Boan Biotech received FDA clearance to begin clinical trials in the U.S. for BA1302, a novel CD228-targeting ADC […]
Weekly Digest – June 2025 Weekly Digest – June 2025 16 June 2025: SunRock Biopharma and Escugen forge alliance to develop first-in-class CCR9-targeted ADC SunRock Biopharma and Escugen have partnered to co-develop SRB123, a first-in-class ADC targeting CCR9, an antigen […]
Weekly Digest – June 2025 Weekly Digest – June 2025 16 June 2025: NextCure and Simcere Zaiming announce strategic partnership for a novel antibody-drug conjugate targeting CDH6 NextCure and Simcere Zaiming have partnered to develop SIM0505, a novel CDH6-targeting ADC […]
Weekly Digest – June 2025 Weekly Digest – June 2025 18 June 2025: IDeate-Prostate01 Phase 3 trial of Ifinatamab Deruxtecan initiated in patients with pretreated metastatic castration-resistant prostate cancer The IDeate-Prostate01 Phase 3 trial has begun, evaluating Ifinatamab deruxtecan (I-DXd) […]
Weekly Digest – June 2025 Weekly Digest – June 2025 16 June 2025: Debiopharm’s ADC research gains momentum with launch of first-in-human trial assessing Debio 1562M in acute myeloid leukemia patients Debiopharm has dosed the first patient in a Phase […]
